• Deferiprone in Tumor Iron Metabolism: Precision Tools for Ir

  2026-06-11

  Explore how Deferiprone enables advanced studies of iron metabolism and apoptosis induction in cancer biology. This article offers a mechanistic deep dive, protocol insights, and practical research applications beyond existing guides.

• Lycopene Mitigates DON-Induced Gut Barrier Injury via ERK Pa

  2026-06-11

  This study presents novel evidence that lycopene protects intestinal epithelial cells from deoxynivalenol (DON)-induced barrier dysfunction and inflammation by targeting the ERK pathway. These findings clarify the mechanistic basis for dietary antioxidant intervention against mycotoxin-induced gut injury and highlight the ERK signaling axis as a therapeutic target.

• VX-765 and VRT-043198: Precision Caspase-1 Inhibition in Mod

  2026-06-10

  Explore how VX-765, a potent caspase-1 inhibitor, advances precision inflammation and cell death studies. This article uniquely connects functional genomic screening innovations with practical assay design for selective cytokine modulation.

• Reliable Cell Assays Using CK2 and ERK8 Inhibitor (SKU B7464

  2026-06-10

  This article explores how CK2 and ERK8 inhibitor (SKU B7464), a high-purity small molecule inhibitor, addresses common challenges in cell viability and kinase signaling assays. Scenario-driven Q&A blocks provide evidence-based strategies for reproducibility and data quality, highlighting how this research-use-only compound from APExBIO supports rigorous biochemical research.

• Neuroligin 1 Loss Drives Repetitive Behaviors via D2-MSN Hyp

  2026-06-09

  This study uncovers how Neuroligin 1 deficiency in striatal D2 receptor-expressing medium spiny neurons (D2-MSNs) leads to autistic-like repetitive behaviors through PKC overactivation and neuronal hyperexcitability. These findings clarify cellular mechanisms underlying restricted and repetitive behaviors in autism spectrum disorder, offering new molecular intervention points for translational neuroscience.

• CX-4945 (Silmitasertib): Applied CK2 Inhibition in Cancer an

  2026-06-09

  CX-4945 (Silmitasertib) is redefining selective CK2 inhibition, powering both cancer and antiviral research with robust, reproducible protocols. This article delivers actionable workflows, troubleshooting strategies, and data-driven insights—bridging oncology and virology with confidence.

• Hemagglutinin mRNA Vaccine Protects Dairy Cows from H5N1

  2026-06-08

  This study demonstrates that a hemagglutinin-based mRNA vaccine delivered via lipid nanoparticles induces robust and durable protection against H5N1 influenza in lactating dairy cows. The results highlight the practical feasibility of mRNA platforms for veterinary applications and inform future vaccine strategies in livestock and zoonotic disease control.

• Otilonium Bromide: Applied Antimuscarinic Workflows in Resea

  2026-06-08

  Otilonium Bromide empowers precise modulation of muscarinic pathways in neuroscience and smooth muscle studies. This article delivers actionable protocols, advanced troubleshooting, and comparative insight—backed by APExBIO’s high-purity formulation—for robust cholinergic signaling research.

• AP20187: Chemical Inducer of Dimerization for Regulated Cell

  2026-06-07

  AP20187 is a synthetic, cell-permeable chemical inducer of dimerization widely used in regulated cell therapy and conditional gene expression. Its high purity, robust solubility, and validated in vivo efficacy make it a gold-standard tool for fusion protein dimerization and metabolic research.

• Flumequine: Redefining DNA Topoisomerase II Inhibition in Tr

  2026-06-06

  Explore how Flumequine, a selective DNA topoisomerase II inhibitor, transforms experimental precision and strategy for translational researchers. This thought-leadership article blends mechanistic insights with actionable guidance, drawing on in vitro cancer drug response paradigms and integrating workflow optimization, protocol recommendations, and a vision for next-generation DNA replication research.

• Entecavir (BMS200475): Mechanisms and Clinical Impact in HBV

  2026-06-05

  Explore the mechanistic depth and clinical significance of Entecavir in chronic hepatitis B virus therapy. This article offers a unique, evidence-driven analysis of its pharmacodynamics, resistance profile, and advanced applications, providing insights beyond standard protocol guidance.

• Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis

  2026-06-05

  This study establishes a novel ferroptosis-related gene signature for predicting hepatocellular carcinoma (HCC) outcomes and identifies Atorvastatin as a promising therapeutic agent based on bioinformatic screening and experimental validation. The findings highlight new avenues for prognosis and ferroptosis-targeted therapy in HCC.

• Thymoquinone in Cardiotoxicity Research: Protocols & Innovat

  2026-06-04

  Thymoquinone, or 2-isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione, sets a new benchmark for modeling and mitigating doxorubicin-induced cardiotoxicity through Nrf2/HO-1 pathway activation and robust antioxidant action. This article delivers actionable workflows, troubleshooting strategies, and evidence-driven tips for maximizing research reproducibility with APExBIO's thymoquinone.

• L-Alanyl-L-Glutamine: Reliable Intestinal Barrier Support

  2026-06-04

  L-Alanyl-L-Glutamine (SKU B8228) addresses the instability and solubility challenges of standard glutamine in gastrointestinal research. It is best suited for workflows requiring stable, water-soluble glutamine supplementation to support intestinal mucosa and barrier function. It should not be used in protocols that require DMSO or ethanol solubility, or where long-term aqueous storage is unavoidable.

• LNP-mRNA Vaccine Targeting Chlamydia psittaci: Immune Protec

  2026-06-03

  A recent study demonstrates that lipid nanoparticle-delivered mRNA encoding the major outer membrane protein (MOMP) of Chlamydia psittaci induces robust protective immune responses in BALB/c mice. This work provides both a methodological framework and preclinical efficacy evidence, informing future RNA vaccine development against zoonotic respiratory pathogens.

422 records 13/29 page Previous Next First page 上5页 1112131415 下5页 Last page